Janaki Kanumilli, MD
Adult Medicine · Mineola, NYNPI 1912956889
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,802 of the $9,059 with a category attached, or 86.1%. It is spread thinly across 37 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,012 and has fallen 96.8% since, to $97 in 2024. Among adult medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 253 payments — averaging $35.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Biohaven Pharmaceuticals, Inc.$1K
- Lilly USA, LLC$848
- AstraZeneca$550
- Neurocrine Biosciences, Inc.$511
- Novo Nordisk$501
- plus $4K from 31 others
What the payments were for
- Consulting fees$1,20013%
- Speaking & faculty fees$571%
- Food & beverage$7,80286%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 56 | $1,681 |
| Biohaven Pharmaceuticals, Inc. | 3 | $1,331 |
| Lilly USA, LLC | 34 | $848 |
| AstraZeneca(2 entities) | 12 | $550 |
| Neurocrine Biosciences, Inc. | 10 | $511 |
| Novo Nordisk | 22 | $501 |
| Eisai Inc. | 8 | $485 |
| Boehringer Ingelheim | 9 | $304 |
| Bayer | 4 | $262 |
| GSK | 4 | $261 |
| SK Life Science, Inc. | 12 | $258 |
| Intuity Medical Inc | 2 | $233 |
| Amgen(2 entities) | 4 | $200 |
| Novartis | 19 | $189 |
| Sunovion Pharmaceuticals Inc. | 8 | $149 |
| Cequr Corporation | 1 | $142 |
| Abbott | 1 | $125 |
| Aurinia Pharma U.S., Inc. | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 6 | $116 |
| Merck | 2 | $111 |
| Acorda Therapeutics, Inc | 5 | $106 |
| Neurelis, Inc. | 4 | $97 |
| MDD US Operations, LLC | 4 | $75 |
| Avanir Pharmaceuticals, Inc. | 3 | $64 |
| Vertical Pharmaceuticals, LLC | 3 | $53 |
| Kowa Pharmaceuticals America, Inc. | 2 | $44 |
| Lundbeck LLC | 2 | $41 |
| GE HealthCare | 2 | $31 |
| UCB, Inc. | 2 | $31 |
| Sanofi | 1 | $22 |
| Biogen | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Grifols USA, LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Pfizer | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,325
- BOTOX$686
- Fycompa$247
- Pogo Automatic Blood Glucose Monitoring System$233
- INGREZZA$175
- ONGENTYS$161
- CeQur Simplicity$142
- SOLIRIS$132
- JARDIANCE$125
- FreeStyle Libre Pro$125
- LOKELMA$125
- Dayvigo$125
- LUPKYNIS$125
- XCOPRI$125
- FARXIGA$125
- Kerendia$125
- TEPEZZA$125
- MOUNJARO$125
- UBRELVY$124
- Ozempic$120
How this compares
$9,059 in reported general payments places this provider in the 90th percentile of 101 adult medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 96 | $35,786 |
| JardianceEmpagliflozin | 25 | $32,515 |
| MounjaroTirzepatide | 17 | $25,864 |
| TrulicityDulaglutide | 22 | $25,710 |
| XareltoRivaroxaban | 49 | $15,838 |
| FarxigaDapagliflozin Propanediol | 19 | $14,899 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $14,357 |
| JanuviaSitagliptin Phosphate | 21 | $10,524 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $8,009 |
| Cinacalcet Hcl | 42 | $4,605 |
| Levothyroxine Sodium | 176 | $2,360 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $2,272 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $2,133 |
| Novolog FlexpenInsulin Aspart | 12 | $2,106 |
| Atorvastatin Calcium | 160 | $1,880 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $848 | $52,17158 claims |
| PfizerEliquis | $15 | $35,78696 claims |
| Boehringer IngelheimJardiance | $304 | $32,51525 claims |
| MerckJanumet, Januvia | $111 | $24,88237 claims |
| AstraZenecaFarxiga | $550 | $14,89919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 101 adult medicine providers in New York.
Other adult medicine in Mineola
- Michael AlaimoMalverne$18K
- Vipin OhriWarsaw$14K
- Yuqing ZhangFlushing$13K
- Chidambaranathan ChandrasekaranPatchogue$13K
- Adam CarpentieriMassapequa$11K
- Cary DanielBrooklyn$10K
- Zeeshan KhanOceanside$9K
- Thomas MolnarJamaica$8K
- Tehmina NaveedPlainview$8K
- Simon LiBrooklyn$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.